Bioactive Laboratories – Welcomes new investors, kicks off new drug development project & celebrates TGA milestone
<Press release for Wholesale Investor>
Bioactive Laboratories welcomes its new investors, thanks existing shareholders & continues to invite SMSF investors to its register.
The Therapeutics subsidiary is powering ahead with the New Molecule Discovery project at the Griffith Institute for Drug Discovery. The significance of this project, in creating a compound library, will add to Bioactive’s IP register of patents for commercial licensing.
The Natural Health subsidiary, creating optimised extracts, submitted its TGA New Substance application in June. This important milestone firms up customer relationships and opens the door to an FDA submission in the near future.
Bioactive have discovered new plant sourced molecules creating first-in-class stomach friendly anti-inflammatory and anti-microbial agents. These collectively service the global market of 7 billion people.
An investor exit is planned looking towards either a listing or a trade sale.